Advertisement

Specific Lymphocyte Proliferative Response In Vitro after cDNA HBsAg Immunization

  • A. Degrassi
  • E. Mariani
  • P. Roda
  • R. Miniero
  • M. Capelli
  • M. C. Honorati
  • A. Astaldi
  • A. Facchini
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 257)

Abstract

The protective mechanism of hepatitis B vaccination using surface antigen is the induction of neutralizing antibodies. Hepatitis B surface Antigen (HBsAg) has proven to be well tolerated and effective in many clinical trials 1,2.

Keywords

Proliferative Response Seroconversion Rate Geometric Mean Titre Lymphocyte Proliferative Response Lymphocyte Proliferative Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    W. Szmuness, C. E. Stevens, E. J. Harley, E. A. Zang, W. R. Oleszko, D. C. William, R. Sadowsky, J. M. Morrison, and A. Kellner, Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the united States, N. Engl. J. Med. 303: 833 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    W. Szmuness, C. E. Stevens, E. A. Zang, E. J. Harley, and A. Keffner, A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report, Hepatology 1: 377 (1981)PubMedCrossRefGoogle Scholar
  3. 3.
    W. J. McAleer, E. B. Buynac, R. Z. Maigetter, D. E. Wampler, W. J. Miller, and M. R. Hilleman, Human hepatitis B vaccine from recombinant yeast, Nature 307: 178 (1984)PubMedCrossRefGoogle Scholar
  4. 4.
    W. Jilg, B. Lorbeer, M. Shmidt, B. Wilske, G Zoulek, and F. Deinhardt, Clinical evaluation of a recombinant hepatitis B vaccine, Lancet ii: 1174 (1984)CrossRefGoogle Scholar
  5. 5.
    T. R. Cupps, J. L. Grein, R. H. Purcell, P. K. Goldsmith, and A. S. Fauci, In vitro antigen-induced antibody response hepatitis B surface antigen in man, J. Clin Invest. 74: 1204 (1984)PubMedCrossRefGoogle Scholar
  6. 6.
    G. Fattovich, A. Alberti, C. Crivellaro, P. Pontisso, F. Noventa, and G. Realdi, Cellular immunity to the hepatitis B virion in acute hepatitis type B, Clin. Exp. Immunol. 53: 645 (1983)PubMedGoogle Scholar
  7. 7.
    U. Hellstrom, S. Sylvan, and P. Lundberg, Regulatory functions of T- and accessory-cells for hepatitis B surface antigen induced specific antibody production and proliferation of human peripheral blood lymphocytes, in vitro, J. Clin. Lab. Immunol. 16: 173 (1985)PubMedGoogle Scholar
  8. 8.
    M. W. Steward, B. M. Sisley, C. Stanley, S. E. Brown , and C. R. Howard, Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions, Clin. Exp. Immunol. 71: 19 (1988)PubMedGoogle Scholar
  9. 9.
    L. G. Filion, R. Saginur, and N. Szczerbak, Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination, Clin. Exp. Immunol. 71: 405 (1988)PubMedGoogle Scholar
  10. 10.
    A. Weinberg, and T. C. Merigan, Recombinant interleukin-2 as an adjuvant for vaccined-induced protection, J. Immunol. 140: 294 (1988)PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • A. Degrassi
    • 1
  • E. Mariani
    • 1
  • P. Roda
    • 1
  • R. Miniero
    • 1
  • M. Capelli
    • 1
  • M. C. Honorati
    • 1
  • A. Astaldi
    • 1
  • A. Facchini
    • 1
  1. 1.Istituto di Clinica Medica e Gastroenterologia, Laboratorio CentralizzatoUniversita’ di Bologna, Istituti Ortopedici Rizzoli, Bologna, Smith Kline & FrenchMilanoItaly

Personalised recommendations